NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021

Swerdlow SH, Harris NL, Jaffe ES, et al.. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France: IARC; 2017.

Swerdlow SH, Harris NL, Jaffe ES, . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France:IARC; 2017.)| false
• Search Google Scholar
• Export Citation

Foss FM, Horwitz SM, Civallero M, et al.. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol 2020;95:151–155.

• Crossref
Foss FM, Horwitz SM, Civallero M, . Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol 2020;95:151–155.10.1002/ajh.25674)| false
• Search Google Scholar
• Export Citation

Gratzinger D, de Jong D, Jaffe ES, et al.. T- and NK-cell lymphomas and systemic lymphoproliferative disorders and the immunodeficiency setting: 2015 SH/EAHP workshop report–part 4. Am J Clin Pathol 2017;147:188–203.

• Crossref
Gratzinger D, de Jong D, Jaffe ES, . T- and NK-cell lymphomas and systemic lymphoproliferative disorders and the immunodeficiency setting: 2015 SH/EAHP workshop report–part 4. Am J Clin Pathol 2017;147:188–203.10.1093/ajcp/aqw213)| false
• Search Google Scholar
• Export Citation

Pro B, Allen PB, Behdad A. Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood 2020;blood.2019004118.

Pro B, Allen PB, Behdad A. Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood 2020;blood.2019004118.)| false
• Search Google Scholar
• Export Citation

Parakkal D, Sifuentes H, Semer R, et al.. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 2011;23:1150–1156.

• Crossref
• PubMed
Parakkal D, Sifuentes H, Semer R, . Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 2011;23:1150–1156.10.1097/MEG.0b013e32834bb90a21941193)| false
• Search Google Scholar
• Export Citation

Yabe M, Medeiros LJ, Daneshbod Y, et al.. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review. Ann Diagn Pathol 2017;26:16–22.

• Crossref
• PubMed
Yabe M, Medeiros LJ, Daneshbod Y, . Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review. Ann Diagn Pathol 2017;26:16–22.2803870610.1016/j.anndiagpath.2016.10.005)| false
• Search Google Scholar
• Export Citation

Daver N, McClain K, Allen CE, et al.. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 2017;123:3229–3240.

• Crossref
• PubMed
Daver N, McClain K, Allen CE, . A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 2017;123:3229–3240.2862180010.1002/cncr.30826)| false
• Search Google Scholar
• Export Citation

Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol 2018;74:5–16.

• Crossref
• PubMed
Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol 2018;74:5–16.10.1016/j.humpath.2018.01.00529337025)| false
• Search Google Scholar
• Export Citation

Farcet JP, Gaulard P, Marolleau JP, et al.. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 1990;75:2213–2219.

• Crossref
• PubMed
Farcet JP, Gaulard P, Marolleau JP, . Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 1990;75:2213–2219.10.1182/blood.V75.11.2213.22132140703)| false
• Search Google Scholar
• Export Citation

Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000;14:991–997.

• Crossref
• PubMed
Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000;14:991–997.1086596310.1038/sj.leu.2401784)| false
• Search Google Scholar
• Export Citation

Suarez F, Wlodarska I, Rigal-Huguet F, et al.. Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. Am J Surg Pathol 2000;24:1027–1032.

• Crossref
• PubMed
Suarez F, Wlodarska I, Rigal-Huguet F, . Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. Am J Surg Pathol 2000;24:1027–1032.10.1097/00000478-200007000-0001610895827)| false
• Search Google Scholar
• Export Citation

Macon WR, Levy NB, Kurtin PJ, et al.. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 2001;25:285–296.

• Crossref
• PubMed
Macon WR, Levy NB, Kurtin PJ, . Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 2001;25:285–296.10.1097/00000478-200103000-0000211224598)| false
• Search Google Scholar
• Export Citation

Yabe M, Medeiros LJ, Tang G, et al.. Prognostic factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases. Am J Surg Pathol 2016;40:676–688.

• Crossref
• PubMed
Yabe M, Medeiros LJ, Tang G, . Prognostic factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases. Am J Surg Pathol 2016;40:676–688.2687201310.1097/PAS.0000000000000614)| false
• Search Google Scholar
• Export Citation

Shi Y, Wang E. Hepatosplenic T-cell lymphoma: a clinicopathologic review with an emphasis on diagnostic differentiation from other T-cell/natural killer-cell neoplasms. Arch Pathol Lab Med 2015;139:1173–1180.

• Crossref
• PubMed
Shi Y, Wang E. Hepatosplenic T-cell lymphoma: a clinicopathologic review with an emphasis on diagnostic differentiation from other T-cell/natural killer-cell neoplasms. Arch Pathol Lab Med 2015;139:1173–1180.2631745610.5858/arpa.2014-0079-RS)| false
• Search Google Scholar
• Export Citation

Cooke CB, Krenacs L, Stetler-Stevenson M, et al.. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996;88:4265–4274.

• Crossref
• PubMed
Cooke CB, Krenacs L, Stetler-Stevenson M, . Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996;88:4265–4274.894386310.1182/blood.V88.11.4265.bloodjournal88114265)| false
• Search Google Scholar
• Export Citation

Wang CC, Tien HF, Lin MT, et al.. Consistent presence of isochromosome 7q in hepatosplenic T gamma/delta lymphoma: a new cytogenetic-clinicopathologic entity. Genes Chromosomes Cancer 1995;12:161–164.

• Crossref
Wang CC, Tien HF, Lin MT, . Consistent presence of isochromosome 7q in hepatosplenic T gamma/delta lymphoma: a new cytogenetic-clinicopathologic entity. Genes Chromosomes Cancer 1995;12:161–164.10.1002/gcc.2870120302)| false
• Search Google Scholar
• Export Citation

Yao M, Tien HF, Lin MT, et al.. Clinical and hematological characteristics of hepatosplenic T gamma/delta lymphoma with isochromosome for long arm of chromosome 7. Leuk Lymphoma 1996;22:495–500.

• Crossref
Yao M, Tien HF, Lin MT, . Clinical and hematological characteristics of hepatosplenic T gamma/delta lymphoma with isochromosome for long arm of chromosome 7. Leuk Lymphoma 1996;22:495–500.10.3109/10428199609054788)| false
• Search Google Scholar
• Export Citation

Alonsozana EL, Stamberg J, Kumar D, et al.. Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma. Leukemia 1997;11:1367–1372.

• Crossref
• PubMed
Alonsozana EL, Stamberg J, Kumar D, . Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma. Leukemia 1997;11:1367–1372.10.1038/sj.leu.24007429264394)| false
• Search Google Scholar
• Export Citation

Wlodarska I, Martin-Garcia N, Achten R, et al.. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 2002;33:243–251.

• Crossref
• PubMed
Wlodarska I, Martin-Garcia N, Achten R, . Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 2002;33:243–251.10.1002/gcc.1002111807981)| false
• Search Google Scholar
• Export Citation

Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, et al.. Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PLoS One 2014;9:e102977.

• Crossref
Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, . Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PLoS One 2014;9:e102977.10.1371/journal.pone.0102977)| false
• Search Google Scholar
• Export Citation

Travert M, Huang Y, de Leval L, et al.. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 2012;119:5795–5806.

• Crossref
• PubMed
Travert M, Huang Y, de Leval L, . Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 2012;119:5795–5806.10.1182/blood-2011-12-39615022510872)| false
• Search Google Scholar
• Export Citation

Nicolae A, Xi L, Pittaluga S, et al.. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia 2014;28:2244–2248.

• Crossref
• PubMed
Nicolae A, Xi L, Pittaluga S, . Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia 2014;28:2244–2248.10.1038/leu.2014.20024947020)| false
• Search Google Scholar
• Export Citation

McKinney M, Moffitt AB, Gaulard P, et al.. The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov 2017;7:369–379.

• Crossref
• PubMed
McKinney M, Moffitt AB, Gaulard P, . The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov 2017;7:369–379.10.1158/2159-8290.CD-16-033028122867)| false
• Search Google Scholar
• Export Citation

Jerez A, Clemente MJ, Makishima H, et al.. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012;120:3048–3057.

• Crossref
• PubMed
Jerez A, Clemente MJ, Makishima H, . STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012;120:3048–3057.2285960710.1182/blood-2012-06-435297)| false
• Search Google Scholar
• Export Citation

Koskela HL, Eldfors S, Ellonen P, et al.. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905–1913.

• Crossref
• PubMed
Koskela HL, Eldfors S, Ellonen P, . Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905–1913.10.1056/NEJMoa111488522591296)| false
• Search Google Scholar
• Export Citation

Ohgami RS, Ma L, Merker JD, et al.. STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia 2013;27:2244–2247.

• Crossref
• PubMed
Ohgami RS, Ma L, Merker JD, . STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia 2013;27:2244–2247.10.1038/leu.2013.10423563237)| false
• Search Google Scholar
• Export Citation

Blombery P, Thompson ER, Jones K, et al.. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica 2016;101:e387–390.

• Crossref
• PubMed
Blombery P, Thompson ER, Jones K, . Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica 2016;101:e387–390.2719871610.3324/haematol.2016.146118)| false
• Search Google Scholar
• Export Citation

Yabe M, Medeiros LJ, Wang SA, et al.. Distinguishing between hepatosplenic T-cell lymphoma and γδ T-cell large granular lymphocytic leukemia: a clinicopathologic, immunophenotypic, and molecular analysis. Am J Surg Pathol 2017;41:82–93.

• Crossref
• PubMed
Yabe M, Medeiros LJ, Wang SA, . Distinguishing between hepatosplenic T-cell lymphoma and γδ T-cell large granular lymphocytic leukemia: a clinicopathologic, immunophenotypic, and molecular analysis. Am J Surg Pathol 2017;41:82–93.10.1097/PAS.000000000000074327755009)| false
• Search Google Scholar
• Export Citation

Malani A, Weigand R, Gupta V, et al.. Ehrlichiosis mimicking T-cell lymphoma/leukemia [abstract] Blood 2005;106:Abstract 4343.

• Crossref
Malani A, Weigand R, Gupta V, . Ehrlichiosis mimicking T-cell lymphoma/leukemia [abstract] Blood 2005;106:Abstract 4343.10.1182/blood.V106.11.4343.4343)| false
• Search Google Scholar
• Export Citation

Marko D, Perry AM, Ponnampalam A, et al.. Cytopenias and clonal expansion of gamma/delta T-cells in a patient with anaplasmosis: a potential diagnostic pitfall. J Clin Exp Hematop 2017;56:160–164.

• Crossref
Marko D, Perry AM, Ponnampalam A, . Cytopenias and clonal expansion of gamma/delta T-cells in a patient with anaplasmosis: a potential diagnostic pitfall. J Clin Exp Hematop 2017;56:160–164.10.3960/jslrt.56.160)| false
• Search Google Scholar
• Export Citation

Cho MW, Chin BB. 18F-FDG PET/CT findings in hepatosplenic gamma-delta T-cell lymphoma: case reports and review of the literature. Am J Nucl Med Mol Imaging 2018;8:137–142.

• PubMed
Cho MW, Chin BB. ¹⁸F-FDG PET/CT findings in hepatosplenic gamma-delta T-cell lymphoma: case reports and review of the literature. Am J Nucl Med Mol Imaging 2018;8:137–142.29755847)| false
• Search Google Scholar
• Export Citation

Belhadj K, Reyes F, Farcet JP, et al.. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261–4269.

• Crossref
• PubMed
Belhadj K, Reyes F, Farcet JP, . Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261–4269.10.1182/blood-2003-05-167512907441)| false
• Search Google Scholar
• Export Citation

Falchook GS, Vega F, Dang NH, et al.. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009;20:1080–1085.

• Crossref
• PubMed
Falchook GS, Vega F, Dang NH, . Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009;20:1080–1085.1923747910.1093/annonc/mdn751)| false
• Search Google Scholar
• Export Citation

Voss MH, Lunning MA, Maragulia JC, et al.. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013;13:8–14.

• Crossref
• PubMed
Voss MH, Lunning MA, Maragulia JC, . Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013;13:8–14.2310791510.1016/j.clml.2012.09.002)| false
• Search Google Scholar
• Export Citation

Klebaner D, Koura D, Tzachanis D, et al.. Intensive induction therapy compared with CHOP for hepatosplenic T-cell lymphoma. Clin Lymphoma Myeloma Leuk 2020;20:431–437.e2.

• Crossref
• PubMed
Klebaner D, Koura D, Tzachanis D, . Intensive induction therapy compared with CHOP for hepatosplenic T-cell lymphoma. Clin Lymphoma Myeloma Leuk 2020;20:431–437.e2.3228429710.1016/j.clml.2019.10.007)| false
• Search Google Scholar
• Export Citation

Gopcsa L, Bányai A, Tamáska J, et al.. Hepatosplenic gamma delta T-cell lymphoma with leukemic phase successfully treated with 2-chlorodeoxyadenosine. Haematologia (Budap) 2002;32:519–527.

• PubMed
Gopcsa L, Bányai A, Tamáska J, . Hepatosplenic gamma delta T-cell lymphoma with leukemic phase successfully treated with 2-chlorodeoxyadenosine. Haematologia (Budap) 2002;32:519–527.12803128)| false
• Search Google Scholar
• Export Citation

Iannitto E, Barbera V, Quintini G, et al.. Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin. Br J Haematol 2002;117:995–996.

• Crossref
• PubMed
Iannitto E, Barbera V, Quintini G, . Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin. Br J Haematol 2002;117:995–996.1206014510.1046/j.1365-2141.2002.03537_3.x)| false
• Search Google Scholar
• Export Citation

Corazzelli G, Capobianco G, Russo F, et al.. Pentostatin (2′-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas. Haematologica 2005;90:ECR14.

• PubMed
Corazzelli G, Capobianco G, Russo F, . Pentostatin (2′-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas. Haematologica 2005;90:ECR14.15753055)| false
• Search Google Scholar
• Export Citation

Jaeger G, Bauer F, Brezinschek R, et al.. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008;19:1025–1026.

• Crossref
• PubMed
Jaeger G, Bauer F, Brezinschek R, . Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008;19:1025–1026.1837552510.1093/annonc/mdn119)| false
• Search Google Scholar
• Export Citation

Ravandi F, Aribi A, O’Brien S, et al.. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009;27:5425–5430.

• Crossref
• PubMed
Ravandi F, Aribi A, O’Brien S, . Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009;27:5425–5430.1980567410.1200/JCO.2009.22.6688)| false
• Search Google Scholar
• Export Citation

Bennett M, Matutes E, Gaulard P. Hepatosplenic T cell lymphoma responsive to 2′-deoxycoformycin therapy. Am J Hematol 2010;85:727–729.

• Crossref
• PubMed
Bennett M, Matutes E, Gaulard P. Hepatosplenic T cell lymphoma responsive to 2′-deoxycoformycin therapy. Am J Hematol 2010;85:727–729.2065297310.1002/ajh.21774)| false
• Search Google Scholar
• Export Citation

Rashidi A, Cashen AF. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J 2015;5:e318.

• Crossref
• PubMed
Rashidi A, Cashen AF. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J 2015;5:e318.2604738810.1038/bcj.2015.43)| false
• Search Google Scholar
• Export Citation

Tanase A, Schmitz N, Stein H, et al.. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia 2015;29:686–688.

• Crossref
• PubMed
Tanase A, Schmitz N, Stein H, . Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia 2015;29:686–688.2523416610.1038/leu.2014.280)| false
• Search Google Scholar
• Export Citation

Domm JA, Thompson M, Kuttesch JF, et al.. Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature. J Pediatr Hematol Oncol 2005;27:607–610.

• Crossref
• PubMed
Domm JA, Thompson M, Kuttesch JF, . Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature. J Pediatr Hematol Oncol 2005;27:607–610.10.1097/01.mph.0000187431.37369.f516282893)| false
• Search Google Scholar
• Export Citation

Sumi M, Takeda W, Kaiume H, et al.. Successful treatment with reduced-intensity cord blood transplant in a patient with relapsed refractory hepatosplenic T-cell lymphoma. Leuk Lymphoma 2015;56:1140–1142.

• Crossref
Sumi M, Takeda W, Kaiume H, . Successful treatment with reduced-intensity cord blood transplant in a patient with relapsed refractory hepatosplenic T-cell lymphoma. Leuk Lymphoma 2015;56:1140–1142.10.3109/10428194.2014.947613)| false
• Search Google Scholar
• Export Citation

Pan H, Huang J, Li JN, et al.. Successful second allogeneic stem-cell transplantation from the same sibling donor for a patient with recurrent hepatosplenic gamma-delta (γ/δ) T-cell lymphoma: a case report. Medicine (Baltimore) 2018;97:e12941.

• Crossref
• PubMed
Pan H, Huang J, Li JN, . Successful second allogeneic stem-cell transplantation from the same sibling donor for a patient with recurrent hepatosplenic gamma-delta (γ/δ) T-cell lymphoma: a case report. Medicine (Baltimore) 2018;97:e12941.10.1097/MD.000000000001294130383643)| false
• Search Google Scholar
• Export Citation